Revlimid losses lead Bristol Myers Squibb to lower full-year guidance

Bris­tol My­ers Squibb cit­ed low­er Revlim­id sales as a dri­ver of its falling rev­enue in the US in the sec­ond quar­ter of 2023. The can­cer drug brought in just un­der $1.47 bil­lion in Q2, down 41% from the same time last year due to gener­ic com­pe­ti­tion and a greater num­ber of pa­tients…

#bristol #squibb #singledigit